Consistent with this, ALX/FPR2 and its proresolution agonists are defective in human diseases characterized by non resolving inflammation, such as asthma, obesity and atherosclerosis17–20. This evidence concerns the gene FPR2 and obesity due to melanocortin 4 receptor deficiency.